Are you Dr. Binder?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 29 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
200 1st St SW
Rochester, MN 55905Phone+1 507-284-2511
Summary
- Dr. Moritz Binder, MD is an oncologist in Rochester, Minnesota. He is currently licensed to practice medicine in Minnesota. He is affiliated with Mayo Clinic Hospital - Rochester.
Education & Training
Mayo Clinic College of Medicine and Science (Phoenix)Fellowship, Hematology and Medical Oncology, 2017 - 2020- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2017
Albert Ludwigs University Faculty of MedicineClass of 2013
Certifications & Licensure
MN State Medical License 2016 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 50 citationsSuboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.Tucker W. Coston, Prateek Pophali, Rangit Vallapureddy, Terra L. Lasho, Christy Finke
American Journal of Hematology. 2019-05-03 - 14 citationsOncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia.Moritz Binder, Ryan M Carr, Terra L Lasho, Christy M Finke, Abhishek A Mangaonkar
Nature Communications. 2022-03-17 - 72 citationsClinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084...Giacomo Coltro, Abhishek A. Mangaonkar, Terra L. Lasho, Christy Finke, Prateek Pophali
Leukemia. 2020-05-01
Press Mentions
Epigenetic Study Identifies Potential Drug Targets for a Rare Type of Bone Marrow CancerApril 12th, 2022
What’s Next for the Research of the FutureJanuary 22nd, 2020
Other Languages
- German
